Profit Or Loss [Abstract]

Innate Pharma - Filing #2813423

Concept	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Profit or loss [abstract]
Profit (loss) [abstract]
Revenue	—	—	57 674 EUR	—	—	—	—	—	—	—	—	—	—	—	—	24 703 EUR
Profit (loss) from operating activities	—	—	57 425 EUR	—	—	—	—	—	—	—	—	—	—	—	—	47 825 EUR
Finance income	—	—	4 775 EUR	—	—	—	—	—	—	—	—	—	—	—	—	6 344 EUR
Finance costs	—	—	5 321 EUR	—	—	—	—	—	—	—	—	—	—	—	—	3 997 EUR
Profit (loss) before tax	—	—	57 972 EUR	—	—	—	—	—	—	—	—	—	—	—	—	45 478 EUR
Tax expense (income)	—	—	— EUR	—	—	—	—	—	—	—	—	—	—	—	—	— EUR
Profit (loss) from continuing operations	—	—	57 972 EUR	—	—	—	—	—	—	—	—	—	—	—	—	45 478 EUR
Profit (loss) from discontinued operations	—	—	131,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	7 331 EUR
Profit (loss)	— EUR	— EUR	58 103 EUR	— EUR	58 103 EUR	— EUR	— EUR	— EUR	— EUR	— EUR	— EUR	— EUR	52 809 EUR	— EUR	— EUR	52 809 EUR
Earnings per share [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Earnings per share [abstract]
Earnings per share [line items]
Basic earnings per share [abstract]
Basic earnings (loss) per share from continuing operations	—	—	73.00	—	—	—	—	—	—	—	—	—	—	—	—	57.00
Basic earnings (loss) per share from discontinued operations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	9.00
Basic earnings (loss) per share	—	—	73.00	—	—	—	—	—	—	—	—	—	—	—	—	66.00
Diluted earnings per share [abstract]
Diluted earnings (loss) per share from continuing operations	—	—	73.00	—	—	—	—	—	—	—	—	—	—	—	—	57.00
Diluted earnings (loss) per share from discontinued operations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	9.00
Diluted earnings (loss) per share	—	—	73.00	—	—	—	—	—	—	—	—	—	—	—	—	66.00